<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04707833</url>
  </required_header>
  <id_info>
    <org_study_id>2020/0126/HP</org_study_id>
    <nct_id>NCT04707833</nct_id>
  </id_info>
  <brief_title>Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen</brief_title>
  <acronym>SeroCOV</acronym>
  <official_title>Protocol for the Collection of Clinical Samples for Evaluation and Implementation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      At present, the offer of tests for the serological diagnosis of CoVID-19 (detection of IgG,&#xD;
      IgM or IgA antibodies against CoV-2 SARS) is plethoric and is based on the use of a very&#xD;
      large number of rapid diagnostic unit tests, a few dedicated high throughput automated&#xD;
      systems or reagents on existing open systems. The offer will continue to expand in the coming&#xD;
      months.&#xD;
&#xD;
      In order to meet the objectives mentioned by the Prime Minister, and confirmed in the HAS&#xD;
      report of April 16, 2020 and in the opinion n°6 of the COVID-19 scientific council concerning&#xD;
      the potential use of these serological tests at the end of the COVID-19 epidemic, the&#xD;
      Virology laboratory wishes to validate the sensitivity and specificity of the tests it&#xD;
      intends to use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of immunological Abbott Architect SARS-CoV-2 IgG Assay</measure>
    <time_frame>24 months</time_frame>
    <description>Measurement of antibodies against COVID-19 infection (Sensitivity and specificity )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of immunological of EUROIMMUN SARS-CoV-2(IgA) ELISA, EUROIMMUN SARS-CoV-2 (IgG) ELISA, WANTAI SARS-CoV-2 Ab ELISA, WANTAI SARS-CoV-2 IgM ELISA, Diasorin LIAISON SARS CoV-2 S1/S2 IgG, Roche ECL anti-SARS-Cov-2 (combined IgG IgA)</measure>
    <time_frame>24 months</time_frame>
    <description>Measurement of antibodies against COVID-19 infection (Sensitivity and specificity )</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">385</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Patient infected or cured from covid19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with an acute SARS-CoV-2 infection confirmed by a positive RT-PCR, hospitalized in COVID units or in COVID resuscitations,&#xD;
Nurses at the Rouen University Hospital infected with COVID 19, and cured,&#xD;
Patients with a high suggestive clinic for COVID-19 infection but with negative COVID-19 RT-PCR</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serological testing for COVID-19 infection</intervention_name>
    <description>The tests used will be the following:&#xD;
EUROIMMUN SARS-CoV-2(IgA) ELISA ELISA SARS-CoV-2 (IgG) EUROIMMUN WANTAI SARS-CoV-2 Ab ELISA WANTAI SARS-CoV-2 IgM ELISA Abbott Architect SARS-CoV-2 IgG Diasorin SARS LINK CoV-2 S1/S2 IgG Roche ECL anti-SARS-Cov-2 (combined IgG IgM IgA)</description>
    <arm_group_label>Patient infected or cured from covid19</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The inclusion criteria in the retrospective &quot;Negative/Potentially Interfering&quot; group are as&#xD;
        follows :&#xD;
&#xD;
          -  Adult patient sampled prior to the onset of the COVID-19 epidemic (before January&#xD;
             2020)&#xD;
&#xD;
          -  Patient presenting a coronavirus infection other than SARS-CoV-2, or other respiratory&#xD;
             viral infections (influenza, metapneumovirus)&#xD;
&#xD;
          -  Patients for whom a serum is kept in the biocollection declared under the number&#xD;
             AC-2014-2293 and kept in the Institute of Clinical Biology, University Hospital of&#xD;
             Rouen.&#xD;
&#xD;
        The criteria for inclusion in the &quot;acute point infection&quot; group are as follows:&#xD;
&#xD;
          -  Patients screened by a positive RT-PCR for an SARS-CoV-2 infection&#xD;
&#xD;
          -  Patients aged ≥ 18 years old&#xD;
&#xD;
          -  Patients taken in charge in the emergency room / in a unit / in COVID resuscitation at&#xD;
             the Rouen University Hospital.&#xD;
&#xD;
          -  Patients having read and understood the briefing note&#xD;
&#xD;
          -  Non-opposition to participation in the study&#xD;
&#xD;
        The criteria for inclusion in the &quot;Sequential acute infection&quot; group are as follows:&#xD;
&#xD;
          -  Patients with positive RT-PCR for CoV-2-SARS infection&#xD;
&#xD;
          -  Patients aged ≥ 18 years old&#xD;
&#xD;
          -  Taken care of in a COVID unit at the Rouen University Hospital&#xD;
&#xD;
          -  Having read and understood the briefing note and signed the informed consent form&#xD;
&#xD;
        The criteria for inclusion in the &quot;Convalescent&quot; group are as follows:&#xD;
&#xD;
          -  Caregivers working at the UH of Rouen&#xD;
&#xD;
          -  Screened by positive RT-PCR for SARS-CoV-2 infection,&#xD;
&#xD;
          -  Healed for at least one month at the time of inclusion&#xD;
&#xD;
          -  Having read and understood the briefing note and signed the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor person&#xD;
&#xD;
          -  Known Pregnancy&#xD;
&#xD;
          -  Person deprived of liberty by an administrative or judicial decision or person placed&#xD;
             under judicial protection / subtutorship or guardianship&#xD;
&#xD;
          -  Person not affiliated with social security&#xD;
&#xD;
          -  Person who does not understand and speak French&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Christophe Plantier, Professor</last_name>
    <phone>02 32 88 66 72</phone>
    <email>Jc.plantier@chu-rouen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>760031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Mallet</last_name>
    </contact>
    <contact_backup>
      <email>secretariat.dcr@chu-rouen.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

